Back to Nephrology

OUR EXPERTISE AND SERVICES AVAILABLE IN

Glomerular Diseases

Overview

Spherix’s coverage of the glomerular disease market concentrates on the current treatment efforts, as well as the potential promising therapies on the horizon, for FSGS, IgA nephropathy, Alport Syndrome, and membranous nephropathy patients. Market trending reports coupled with patient chart audits and launch trackers provide unique and invaluable insights into these rapidly advancing markets.

Services Available

Exploring the patient journey

  • Alport Syndrome (US) - n=150 patient charts

  • Focal Segmental Glomerulosclerosis (US) - n=500 patient charts

  • IgA Nephropathy (US) - n=500 patient charts

Prepping for the pipeline

  • Focal Segmental Glomerulosclerosis (FSGS) (US) - annual, n=100 patient charts

  • IgA Nephropathy (US) - annual, n=100 patient charts

  • Membranous Nephropathy (US) - annual, n=100 patient charts

  • Glomerular Diseases (EU) - annual, n=100 patient charts

Gauging impact of disruptive events

  • Multi-Specialty Impact of COVID-19 (US)

Learn more about our services

  • HOW CAN WE PARTNER TOGETHER?

    Get more information on Glomerular Diseases Coverage